Drug intelligence / Profile preview

semi-allogeneic fibroblasts transfected with autologous tumor DNA

Development stage: Discontinued
Lead developer: Immune Cell Therapy
Modality: Vaccines & Immunotherapeutics, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies, Gene Addition/Replacement → Gene Therapies, Cell Therapies
Administration: Intradermal

Overview

This is an experimental cancer vaccine approach that involves genetically modifying semi-allogeneic fibroblasts (fibroblasts from a partially matched donor or a cell line) by transfecting them with DNA extracted from the patient's own tumor cells. The goal is for these modified fibroblasts to express and present tumor-associated antigens, thereby stimulating the patient's immune system to recognize and attack their cancer cells. This strategy aims to overcome immune tolerance to tumor antigens and induce a specific anti-tumor T-cell response.

Beyond the preview

Go deeper on semi-allogeneic fibroblasts transfected with autologous tumor DNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on semi-allogeneic fibroblasts transfected with autologous tumor DNA.

Explore the full profile